FUELing the Search for Medical Therapies in Late Fontan Failure.
The Fontan operation has become the final step in the palliation of many patients with single ventricle disease1. Although outcome has undoubtedly improved over the years, late failure is common and notoriously difficult to treat2, 3. In the face of increasing numbers of young failing Fontan patients with heart transplant as the only, high risk exit strategy, the quest for medical therapies to prevent decline and/or treat Fontan failure has reached a new level of urgency. In this issue of Circulation, Goldberg et al. report on their experience with udenafil, a long-acting phosphodiesterase type 5 inhibitor, in 400 adolescents with a Fontan circulation4. The authors have to be congratulated for completing a long awaited large prospective, multicenter, placebo-controlled trial, which showed a small, non-significant improvement in peak oxygen consumption (primary aim) and multiple significant but limited improvements at the ventilatory anaerobic threshold (secondary aims). Although essentially a nearly negative study, and with the clinical relevance of the changes observed still uncertain, this work nevertheless provides invaluable information for clinical practice and further research.